ADCs: The Chemical War Within - A Systems-Level Industry Analysis (2026)
An ADC no longer fails because the target biology was wrong. It fails as a system. This briefing reconstructs four decades of conjugate chemistry, manufacturing, regulation, capital and talent to show where programmes actually die, and why most of those failure points sit outside the biology function entirely.
What this report answers
- Why do antibody-drug conjugates fail as systems rather than as molecules?
- What separates a genuinely ADC-capable CDMO from one that only claims to be?
- Why does preclinical efficacy in animal models translate so poorly into human tumours?
- What changed in how regulators assess an ADC between 2020 and 2026?
- How have licensing deal structures and platform valuations shifted since the funding peak?
- Which leadership gaps determine whether an ADC programme can be executed at all?
74%
the share of ADC complete response letters issued between 2020 and 2024 that the briefing attributes to manufacturing and quality deficiencies rather than to efficacy or safety data.
30%
the salary premium ProGen Search observes on roles working with high-potency compounds under containment, set against the qualification lag the report attaches to the same roles.
What the analysis establishes
The chemistry, not the target, sets the outcome
The report walks the field's failure history from the first-generation potency era through to the payload class now in favour, treating each failure as a chemistry problem rather than a biology one. It establishes which physicochemical properties govern circulation, clearance and tolerability, and shows how far an ADC's adverse event profile is set by linker and payload rather than by the antibody target.
Capability against capacity in the CDMO base
A great many providers now describe themselves as ADC-capable. The briefing separates scientific capability from industrial capacity, sets out the four distinct manufacturing disciplines an ADC forces into a single supply chain, and identifies where the conflicts between them accumulate. It also describes the one downstream step it treats as the hard governor on launch readiness.
What does not survive the move from mouse to human
Preclinical models flatter ADCs in ways the report makes explicit. It sets out why human tumour architecture breaks the linear dose-response seen in xenografts, the conditions under which the widely cited bystander effect stops working, and why the conventional dose-escalation design used across oncology is the wrong instrument for this class of molecule.
The regulatory basis has moved from efficacy to control
Regulators no longer treat an ADC as a single entity. The briefing documents the doctrine that replaced that view, the specification and impurity controls that follow from it, and how liability for a contract manufacturer's inspection findings now sits with the sponsor. It also covers where FDA, EMA and NMPA expectations have diverged, and what post-approval site transfers cost.
Capital, geopolitics and the split in the sector
The report tracks the move from the 2020-2022 funding cycle to a sector split between companies executing on validated chemistry and those trading on platform narrative. It covers how upfront terms have shifted, what a single safety signal now does to a platform valuation, and how biosecurity legislation is reshaping Western licensing of China-originated assets.
Leadership as the gating function
The closing analysis treats talent supply as a gate on industrial scaling rather than a support issue. It identifies the specific profile the industry is short of, quantifies the premium and the qualification lag attached to high-containment operations, and describes the organisational structure the report argues has to replace the legacy chemistry-versus-biology split.
How it was built
A forensic reconstruction rather than a market survey. It works from four decades of published clinical and regulatory outcomes, analysis of complete response letters issued between 2020 and 2024, and a structural review of the ADC supply chain, combined with aggregated and anonymised observations from ProGen Search's own executive search mandates. The report states plainly that its projections, CMC attrition rates and human capital assessments are modelled planning ranges rather than measured outcomes, and should be treated as such.
Written for biotech CEOs and boards, business development and licensing teams, CMC and technical operations leadership, CDMO executives, and investors running diligence on ADC assets.
Contents
- Forensic History and the Chemistry of Failure (1980-2020)
- The Manufacturing Ceiling and Supply Chain Fragility
- The Clinical and Translational Paradox
- The Regulatory Reality Check (2020-2026)
- The Financial and Geopolitical Landscape
- The Talent and Organisational Gating Function
- 2026-2030 Forecast and Modal Collisions
- Strategic mandates, glossary and ADC readiness checklist
Organisations and regulators referenced
BioNTech, Catalent, Daiichi, DualityBio, Hansoh, Kelun-Biotech, Lonza, MacroGenics, Merck, Novo Holdings, Samsung Biologics, WuXi XDC, FDA, EMA, NMPA
The full 17-page briefing is free. Tell us where to send it and it downloads immediately.
The State of ADCs 2026
The flagship ADC report goes further than this briefing: full sector structure, named programmes and operators, and the commercial picture sitting behind the chemistry.
See the full report →